{"id":"NCT00457015","sponsor":"Shire","briefTitle":"Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)","officialTitle":"EDEMA4: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04-01","primaryCompletion":"2008-06-01","completion":"2008-06-01","firstPosted":"2007-04-05","resultsPosted":"2010-05-04","lastUpdate":"2021-06-08"},"enrollment":96,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema (HAE)"],"interventions":[{"type":"DRUG","name":"ecallantide","otherNames":["DX-88"]},{"type":"DRUG","name":"Phosphate Buffer Saline (PBS), pH 7.0","otherNames":[]}],"arms":[{"label":"DX-88 (ecallantide)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of DX-88 (ecallantide) versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.","primaryOutcome":{"measure":"Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose","timeFrame":"baseline, 4 hours post-dose","effectByArm":[{"arm":"KALBITOR (Ecallantide)","deltaMin":2.2,"sd":0.5},{"arm":"Placebo","deltaMin":2,"sd":0.35}],"pValues":[{"comp":"OG000 vs OG001","p":"0.010"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":45,"countries":["United States","Canada","Jordan"]},"refs":{"pmids":["24712435","23878046","23548529","23548526","22765833","21130380"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Headache","Nausea","Diarrhoea","Vomiting"]}}